Purpose: To assess the efficacy and safety of MicroPulse Transscleral Cyclophotocoagulation (MP-TSCPC) in Chinese patients with early to moderate glaucoma over a one-year follow-up. Patients and Methods: This retrospective case series included 11 eyes of 11 consecutive Chinese patients with early to moderate glaucoma who underwent MP-TSCPC between November 2023 and March 2024. All patients were aged 18– 80 years, had a baseline intraocular pressure (IOP) ≥ 21 mmHg, and completed at least 12 months of follow-up. MP-TSCPC was performed using an Iridex Cyclo G6 laser with standardized settings (2000 mW power, 31.3% duty cycle, 160 seconds total). Changes in IOP, the number of anti-glaucoma medications, best-corrected visual acuity (BCVA), surgical success rates, and complications were recorded. Results: At 12 months, mean IOP decreased significantly from 28.64± 12.18 mmHg to 18.09± 7.70 mmHg (P< 0.05), and the mean number of anti-glaucoma medications was reduced from 3.27± 0.91 to 1.64± 1.00 (P< 0.01). BCVA remained stable throughout follow-up. No severe complication occurred, transient mild anterior chamber inflammation resolved with treatment. Conclusion: Despite the small cohort size, MP-TSCPC demonstrates preliminary efficacy and good safety profile in IOP control in Chinese patients with early to moderate glaucoma, significantly lowering IOP and reducing medication burden without negatively impacting visual acuity or causing serious complications. Keywords: intraocular pressure reduction, anti-glaucoma medication burden, surgical safety profile, treatment efficacy, Chinese patient cohort
Li et al. (Thu,) studied this question.